drugset / Trial / NCT05305859
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Phase 2
Recruiting
30 enrolled
The First Affiliated Hospital of Xiamen University
Dongguan People's Hospital · collabFujian Cancer Hospital · collabFujian Provincial Hospital · collabHuizhou Municipal Central Hospital · collabJieyang People's Hospital · collabZhangzhou manicipal hospital of Fujian Province · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
Timeline
- Start
- 2022-01-12
- Primary completion
- 2026-01-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | — |
| Subject | Tucidinostat | Small molecule | 30 mg | — |
| Subject | Venetoclax | Small molecule | 200 mg | — |